Tocilizumab
Top View
- Immunosuppressive Drugs and COVID-19: a Review
- INN Working Document 05.179 Update 2011
- Codes Drug Name J3262 Actemra (Tocilizumab) IV Only C9399, A4641
- A Review on the Effect of COVID-19 in Type 2 Asthma and Its Management
- Immunomodulators
- (INN) for Biological and Biotechnological Substances
- Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab
- Rxoutlook® 3Rd Quarter 2020
- Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- Tocilizumab Intravenous – (M0004)
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Financial and Non-Financial Highlights Chugai Pharmaceutical Co., Ltd
- PRODUCT MONOGRAPH Practemra
- International Nonproprietary Names for Biological and Biotechnological Substances: a Review17
- Specialty Pipeline: March 2021